Trident Texofab Ltd
Trident Texofab Ltd (TTFL) last reported results for the quarter ended Jun 2026, with sales of ₹26.14 crore and net profit of ₹0.52 crore. The next scheduled event is a record date on 12 Oct 2026. The stock last traded at ₹20.2, a market capitalisation of ₹30.2 crore, on a P/E of 26.0. Over the past 52 weeks the stock has ranged between ₹20 and ₹379. Figures are as of 6 Oct 2026 and are not real time.
Trident Texofab Ltd share price and key metrics
- Current price
- ₹20.2
- Market cap
- ₹30.2 cr
- Stock P/E
- 26.0
- Book value
- ₹37.1
- ROE
- 2.74%
- ROCE
- 7.91%
- Dividend yield
- 0.00%
- 52w high / low
- 379/20.0
Metrics as of 6 Oct 2026. Not real time.
Track Trident Texofab Ltd
Cruxal reads every Trident Texofab Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Trident Texofab Ltd growth and returns
- 10 Years
- 6%
- 5 Years
- 19%
- 3 Years
- 7%
- TTM
- -7%
- 10 Years
- 22%
- 5 Years
- 34%
- 3 Years
- -15%
- TTM
- -59%
- 10 Years
- %
- 5 Years
- -13%
- 3 Years
- -33%
- 1 Year
- -94%
- 10 Years
- 5%
- 5 Years
- 4%
- 3 Years
- 2%
- Last Year
- 3%
Trident Texofab Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹26.14 cr, down 6.9% from ₹28.08 cr a year earlier. Net profit was ₹0.52 cr, down 49.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 26.45 | 31.69 | 38.21 | 28.08 | 30.63 | 25.74 | 33.57 | 26.14 |
| Expenses | 26.72 | 29.37 | 36.86 | 26.01 | 28.15 | 24.1 | 34.65 | 24.72 |
| Operating profit | -0.27 | 2.32 | 1.35 | 2.07 | 2.48 | 1.64 | -1.08 | 1.42 |
| OPM % | -1.02% | 7.32% | 3.53% | 7.37% | 8.10% | 6.37% | -3.22% | 5.43% |
| Other income | 2.76 | -0.2 | 0.43 | 0.44 | 0.39 | 0.38 | -0.5 | 0.19 |
| Interest | 1.13 | 1.38 | 0.99 | 0.73 | 0.96 | 0.87 | 0.37 | 0.55 |
| Depreciation | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.38 | 0.38 |
| Profit before tax | 0.95 | 0.33 | 0.38 | 1.37 | 1.5 | 0.74 | -2.33 | 0.68 |
| Tax % | -6.32% | 6.06% | -34.21% | 25.55% | 25.33% | 22.97% | -13.73% | 23.53% |
| Net profit | 1 | 0.3 | 0.51 | 1.02 | 1.13 | 0.57 | -2.01 | 0.52 |
| EPS (₹) | 0.99 | 0.29 | 0.38 | 0.68 | 0.75 | 0.38 | -1.34 | 0.35 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Trident Texofab Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 76 | 85 | 87 | 91 | 50 | 84 | 96 | 99 | 122 | 118 | 116 |
| Operating profit | 1 | 1 | 2 | 5 | 3 | 5 | 8 | 8 | 7 | 6 | 4 |
| OPM % | 1.5% | 1.7% | 2.8% | 5% | 6% | 6% | 9% | 8% | 6% | 5% | 3.8% |
| Net profit | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 3 | 1 | 0 |
| EPS (₹) | 4.12 | 0.78 | 1.32 | 0.94 | 0.35 | 0.97 | 2.20 | 1.07 | 1.85 | 0.47 | 0.14 |
TTM is the trailing twelve months to the most recent quarter.
Trident Texofab Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 0.33 | 4 | 4 | 4 | 10 | 10 | 10 | 10 | 14 | 15 |
| Reserves | 3 | 4 | 7 | 7 | 2 | 3 | 5 | 6 | 34 | 41 |
| Borrowings | 5 | 5 | 15 | 22 | 34 | 39 | 38 | 40 | 30 | 37 |
| Other liabilities | 15 | 32 | 21 | 22 | 22 | 19 | 24 | 26 | 24 | 19 |
| Total liabilities | 24 | 45 | 47 | 56 | 68 | 71 | 77 | 82 | 101 | 111 |
| Fixed assets | 1 | 2 | 2 | 12 | 14 | 22 | 23 | 22 | 20 | 17 |
| CWIP | 0 | 0 | 6 | 0 | 9 | 4 | 0 | 0 | 0 | 1 |
| Investments | 1 | 3 | 1 | 1 | 2 | 2 | 4 | 4 | 2 | 4 |
| Other assets | 22 | 41 | 37 | 42 | 42 | 44 | 50 | 56 | 79 | 90 |
| Total assets | 24 | 45 | 47 | 56 | 68 | 71 | 77 | 82 | 101 | 111 |
As reported by the company. Total assets equal total liabilities by construction.
Trident Texofab Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0 | -2 | -3 | -3 | 2 | 1 | 6 | 3 | -14 | -10 |
| Cash from investing | -1 | -2 | -7 | -2 | -10 | -4 | 0 | -1 | 4 | -6 |
| Cash from financing | 2 | 3 | 10 | 5 | 8 | 3 | -6 | -2 | 12 | 12 |
| Net cash flow | 2 | -2 | 0 | -0 | -0 | 0 | 0 | 0 | 3 | -3 |
| Free cash flow | 0 | -3 | -10 | -4 | -8 | -2 | 6 | 3 | -14 | -13 |
| CFO / operating profit | 27% | -141% | -84% | -49% | 76% | 29% | 73% | 36% | -183% | -137% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Trident Texofab Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 16% | 14% | 12% | 14% | 9% | 8% | 16% | 12% | 10% | 8% |
| Debtor days | 74 | 137 | 123 | 106 | 221 | 134 | 128 | 135 | 122 | 150 |
| Inventory days | 12 | 23 | 18 | 47 | 70 | 37 | 48 | 59 | 55 | 71 |
| Days payable | 75 | 135 | 89 | 74 | 141 | 58 | 80 | 73 | 51 | 45 |
| Cash conversion cycle | 11 | 25 | 53 | 79 | 150 | 113 | 97 | 121 | 126 | 176 |
| Working capital days | 23 | 32 | 37 | 43 | 71 | 42 | 36 | 35 | 85 | 127 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Trident Texofab Ltd shareholding pattern
Promoters held 32.16% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 57.78% | 46.89% | 35.54% | 32.16% | 32.16% | 32.16% | 32.16% | 32.16% |
| Public | 42.22% | 53.11% | 64.46% | 67.84% | 67.84% | 67.85% | 67.84% | 67.85% |
| No. of shareholders | 6,257 | 5,756 | 5,428 | 5,069 | 4,998 | 5,097 | 5,632 | 5,948 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Trident Texofab Ltd events
The next scheduled event is a record date on 12 Oct 2026.
- Record dateRecord date for dividend or corporate action
- AGMApproval of appointment of statutory auditor and other matters
See the full results calendar for every Indian company reporting in the next 30 days.
Trident Texofab Ltd corporate filings
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please find enclosed herewith the Certificate under Regulation 74(5) of SEBI…
Read the full analysis - Trident Texofab Ltd publishes newspaper notice for EGM and e-voting detailsCompany Updatelow impact
Cruxal's analysis: The company has issued a newspaper advertisement regarding the notice of an Extraordinary…
Read the full analysis - Trident Texofab schedules EGM on October 28, 2026, to approve appointment of new statutory auditor, filling casual vacancyAGM/EGMmedium impact
Cruxal's analysis: Trident Texofab Limited has announced an Extraordinary General Meeting (EGM) scheduled…
Read the full analysis - Trident Texofab Approves Appointment of New Statutory Auditor and Calls EGM for Shareholder ApprovalOtherslow impact
Cruxal's analysis: Trident Texofab Limited announced the appointment of M/s. A Bafna & Associates as its…
Read the full analysis - Corporate Voting Results Confirm Majority Support for Financial and Strategic Resolutions at Trident Texofab AGMAGM/EGMhigh impact
Cruxal's analysis: Trident Texofab Limited's AGM held on September 30, 2026, saw strong shareholder approval…
Read the full analysis - Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, we wish to inform you that the Trading Window for dealing in securities of the Company shall remain closed with effect ....Insider Trading / SASTlow impact
- Trident Texofab Limited holds 18th AGM; no immediate financial disclosures or strategic announcementsAGM/EGMlow impact
Cruxal's analysis: Trident Texofab Limited conducted its 18th Annual General Meeting on September 30, 2026…
Read the full analysis - Hardik Desai Family Trust Increases Stake in Trident Texofab Limited via Open Market PurchaseInsider Trading / SASTlow impact
Cruxal's analysis: Trident Texofab Limited's promoter group entity, Hardik Desai Family Trust, has acquired…
Read the full analysis - Trident Texofab Ltd announces 18th Annual General Meeting and e-voting detailsCompany Updatelow impact
Cruxal's analysis: Trident Texofab Ltd has published newspaper advertisements in Financial Express (English…
Read the full analysis - Trident Texofab Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Trident Texofab Ltd has filed its Annual Report for the financial year 2025-26. The…
Read the full analysis - Trident Texofab Limited Announces 18th AGM and Releases Annual Report for FY 2025-26AGM/EGMlow impact
Cruxal's analysis: Trident Texofab Limited has scheduled its 18th Annual General Meeting for September 30…
Read the full analysis - Trident Texofab Ltd schedules 18th Annual General Meeting for September 30, 2026Company Updatelow impact
Cruxal's analysis: Trident Texofab Ltd has published a newspaper advertisement confirming that its 18th…
Read the full analysis - Trident Texofab Limited Announces Board Meeting Outcomes, Including 18th AGM Schedule and Appointment of Cost Auditor for FY 2026-27Otherslow impact
Cruxal's analysis: Trident Texofab Limited has disclosed the outcomes of its board meeting held on September…
Read the full analysis - Trident Texofab Limited voluntarily withdraws credit ratings for bank facilities totaling 20 crore INRCompany Updatelow impact
Cruxal's analysis: Trident Texofab Limited has voluntarily requested and received a withdrawal of its credit…
Read the full analysis - Hardik Desai Family Trust Increases Stake in Trident Texofab Limited via Open Market PurchaseInsider Trading / SASTlow impact
Cruxal's analysis: Hardik Desai Family Trust, part of the promoter group of Trident Texofab Limited, has…
Read the full analysis - Trident Texofab Limited: Promoter Group Increases Stake via Open Market AcquisitionInsider Trading / SASTlow impact
Cruxal's analysis: Trident Texofab Limited's promoter group, Hardik Desai Family Trust, has increased its…
Read the full analysis - Hardik Desai Family Trust Increases Stake in Trident Texofab Limited via Open Market PurchaseInsider Trading / SASTlow impact
Cruxal's analysis: Hardik Desai Family Trust, part of the promoter group of Trident Texofab Limited, has…
Read the full analysis - Hardik Desai Family Trust Increases Stake in Trident Texofab Limited via Open Market PurchaseInsider Trading / SASTlow impact
Cruxal's analysis: Trident Texofab Limited's promoter group entity, Hardik Desai Family Trust, has increased…
Read the full analysis - Trident Texofab Ltd publishes Q1 FY2027 standalone financial results in newspapersCompany Updatelow impact
Cruxal's analysis: Trident Texofab Ltd has fulfilled its regulatory obligation under SEBI LODR by publishing…
Read the full analysis - Trident Texofab Reports Q1 FY27 Financial Results and Announces Resignation of Statutory AuditorBoard Meetingmedium impact
Cruxal's analysis: Trident Texofab Limited reported Q1 FY27 revenue from operations of 26.14 crore, a…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.